Genentech, Inc.

1020 articles with Genentech, Inc.

• Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development

  5/24/2018

  Curis, Inc. today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development.

• 

  Genentech’s Hemlibra Significantly Reduces Bleeding in Late-Stage Hemophilia Studies

  5/21/2018

  Genentech’s hemophilia treatment Hemlibra continues to demonstrate its efficacy in treating patients. New late-stage data presented at World Federation of Hemophilia 2018 World Congress shows the drug significantly reduced treated bleeds in a broad patient population in two separate studies.

• Genentech’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III HAVEN 3 Study in Hemophilia A without Factor VIII Inhibitors

  5/21/2018

  – In a subset of patients in the HAVEN 3 study who previously received factor VIII prophylaxis, the standard of care, HEMLIBRA reduced bleeds by 68 percent compared to their prior therapy – – Phase III HAVEN 4 results showed HEMLIBRA every four weeks provides clinically meaningful control of bleeding in people with or without factor VIII inhibitors –

• coreHEM Publishes Core Outcome Set for Hemophilia Clinical Trials; Prepares to Launch Next Phase of Work

  5/21/2018

  The coreHEM initiative has announced the publication of a core outcome set for clinical trials of gene therapy in hemophilia.

• 

  Genentech’s Alecensa Beats Out Pfizer’s Xalkori in Late-Stage Lung Cancer Trial

  5/17/2018

  Genentech, released follow-up data from its Phase III ALEX trial comparing its Alecensa (alectinib) to Pfizer’s Xalkori (crizotinib) in late-stage non-small cell lung cancer (NSCLC).
• 

  Abstracts Unveiled Ahead of ASCO, One Study Compares Novartis and Gilead CAR-T Therapies

  5/17/2018

  Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
• 

  Genentech Kills IDO Inhibitor Pact with NewLink Genetics

  5/16/2018

  Genentech, has terminated its research program with Ames, Iowa-based NewLink Genetics.
• 

  FDA Approves Pfizer’s Biosimilar to Amgen’s Epogen

  5/16/2018

  The U.S. Food and Drug Administration (FDA) approved Pfizer’s Retacrit (epoetin alfa-epbx), a biosimilar to Amgen’s Epogen/Procrit (epoetin alfa). The drugs treat anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in HIV patients.

• Genentech to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in People With Hemophilia A at the World Federation of Hemophilia 2018 World Congress

  5/14/2018

  Data include results from HAVEN 3 study in people with hemophilia A without factor VIII inhibitors and HAVEN 4 study in people with hemophilia A with or without factor VIII inhibitors

• FDA Approves Subcutaneous Formulation of Actemra for Use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis

  5/14/2018

  Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age and older. Actemra can be given alone or in combination with methotrexate (MTX) in patients with PJIA

• 

  AstraZeneca’s Fasenra Fails in a COPD Clinical Trial

  5/11/2018

  AstraZeneca and its biologics research-and-development arm, MedImmune, indicated that its Fasenra (benralizumab) did not meet its primary endpoint in patients with moderate to very severe COPD.
• 

  Another GSK Executive Departs as Emma Walmsley Continues to Shape Company Leadership

  5/11/2018

  Changes continue at the c-suite level of GlaxoSmithKline. This week another high profile executive, Chief Financial Officer Simon Dingemans announced he will retire from GSK in 2019.
• 

  Newly Merged Amneal Pharmaceuticals to Push into the Biosimilar Space

  5/10/2018

  Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.
• 

  Genentech’s Tecentriq Flunks Phase III for Colorectal Cancer

  5/10/2018

  Genentech reported that its Phase III IMblaze370 trial of Tecentriq (atezolizumab) and Cotellic (cobimetinib) for difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) did not meet its primary endpoint of overall survival (OS) compared to Bayer’s Stivarga (regorafenib).

• Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer

  5/10/2018

  The study did not meet its primary endpoint of improving overall survival versus regorafenib. Results will be submitted for presentation at an upcoming medical meeting.

• 

  Lodo Therapeutics and Genentech Ink Strategic Collaboration Potentially Worth $1 Billion or More

  5/9/2018

  Lodo Therapeutics, based in New York, formed a strategic drug discovery collaboration with Genentech, a Roche company, in a deal potentially worth more than $1 billion.

• Lodo Therapeutics Corporation Forms Multi-Target Strategic Collaboration with Genentech

  5/9/2018

  Collaboration provides Genentech with access to Lodo Therapeutics’ proprietary metagenomics-based natural products drug discovery platform Lodo to receive up to $969 million in upfront fees and milestone payments

• 

  FDA Gives Genentech’s Tecentriq Priority Review for Triple-Combo Lung Cancer Treatment

  5/7/2018

  The U.S. Food and Drug Administration (FDA) granted Genentech’s Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) Priority Review for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
• 

  Gene Therapies for Hemophilia Could Hit $1.5 Million, Analysts Speculate

  5/7/2018

  As we get closer to seeing the U.S. Food and Drug Administration green light the first gene therapy for hemophilia, analysts estimate that the cost of the probable one-time treatment could have a whopping price-tag of $1.5 million.
• 

  The Top 5 Upcoming Biosimilar Approvals in the U.S.

  5/4/2018

  According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.